| 9.155 0.245 (2.75%) | 11-14 13:35 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.9 | 1-year : | 13.19 |
| Resists | First : | 10.19 | Second : | 11.3 |
| Pivot price | 9.97  |
|||
| Supports | First : | 8.39 | Second : | 6.98 |
| MAs | MA(5) : | 9.41 |
MA(20) : | 10.01 |
| MA(100) : | 8.15  |
MA(250) : | 9.99 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 21.7 |
D(3) : | 25.5 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 18.54 | Low : | 4.29 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CVRX ] has closed above bottom band by 10.3%. Bollinger Bands are 16.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.55 - 9.6 | 9.6 - 9.66 |
| Low: | 8.26 - 8.32 | 8.32 - 8.38 |
| Close: | 8.8 - 8.9 | 8.9 - 9.01 |
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Fri, 14 Nov 2025
Will CVRx Inc. stock maintain growth story - Quarterly Trade Report & Proven Capital Preservation Methods - newser.com
Thu, 13 Nov 2025
Can swing trading help recover from CVRx Inc. losses - Market Weekly Review & Verified Entry Point Signals - newser.com
Thu, 13 Nov 2025
A Quick Look at Today's Ratings for CVRx Inc(CVRX.US), With a Forecast Between $11 to $14 - 富途牛牛
Tue, 11 Nov 2025
Johnson & Johnson Makes a Major Move with CVRx Stock Sale! - TipRanks
Mon, 10 Nov 2025
Johnson & Johnson innovation sells CVRx (CVRX) shares worth $536,309 - Investing.com
Mon, 10 Nov 2025
Insider Sale: 10% owner at $CVRX Sells 200 Shares - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 26 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 67.6 (%) |
| Shares Short | 1,800 (K) |
| Shares Short P.Month | 1,870 (K) |
| EPS | -2.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.22 |
| Profit Margin | -95.7 % |
| Operating Margin | -105.8 % |
| Return on Assets (ttm) | -29.7 % |
| Return on Equity (ttm) | -92.4 % |
| Qtrly Rev. Growth | 15.1 % |
| Gross Profit (p.s.) | 1.75 |
| Sales Per Share | 2.09 |
| EBITDA (p.s.) | -1.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -4.44 |
| PEG Ratio | 0 |
| Price to Book value | 4.11 |
| Price to Sales | 4.35 |
| Price to Cash Flow | -6.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|